Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
OCUL

OCUL - Ocular Therapeutix Inc Stock Price, Fair Value and News

7.85USD+0.10 (+1.29%)Market Closed

Market Summary

OCUL
USD7.85+0.10
Market Closed
1.29%

OCUL Stock Price

View Fullscreen

OCUL RSI Chart

OCUL Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-10.55

Price/Sales (Trailing)

20.32

Price/Free Cashflow

-13.96

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-28.25%

Return on Assets

-21.39%

Free Cashflow Yield

-7.16%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

59.8M

Rev. Growth (Yr)

10.47%

Rev. Growth (Qtr)

-0.19%

OCUL Earnings

Earnings (TTM)

-115.3M

Earnings Growth (Yr)

-113.89%

Earnings Growth (Qtr)

-121.93%

Breaking Down OCUL Revenue

Last 7 days

-3.4%

Last 30 days

43.0%

Last 90 days

50.4%

Trailing 12 Months

74.1%

How does OCUL drawdown profile look like?

OCUL Financial Health

Current Ratio

21.39

Debt/Equity

0.02

Debt/Cashflow

-9.21

OCUL Investor Care

Shares Dilution (1Y)

99.79%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202459.8M000
202351.7M54.6M57.7M58.4M
202249.4M49.9M49.7M51.5M
202122.1M32.3M38.6M43.5M
20206.3M7.3M12.3M17.4M
20192.1M2.1M2.5M4.2M
20181.8M2.0M2.0M2.0M
20171.9M1.9M1.9M1.9M
20161.8M1.8M1.8M1.9M
20151.2M1.5M1.8M1.8M
2014200.5K391.0K581.5K772.0K
201200010.0K
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ocular Therapeutix Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 01, 2024
waheed nadia
acquired
-
-
141,666
chief medical officer
May 23, 2024
nayak sanjay
sold
-13,280
5.84
-2,274
chief strategy officer
May 23, 2024
dugel pravin
sold
-125,215
5.79
-21,626
see remarks
Feb 26, 2024
summer road llc
bought
7,000,000
7.52
930,851
-
Feb 22, 2024
nayak sanjay
acquired
-
-
80,300
chief strategy officer
Feb 22, 2024
dugel pravin
acquired
-
-
854,979
executive chairman
Feb 05, 2024
strassburger philip c.
acquired
29,300
4.86
6,029
general counsel
Feb 05, 2024
ozden rabia gurses
acquired
30,841
4.86
6,346
chief medical officer
Feb 05, 2024
notman donald
acquired
30,190
4.86
6,212
chief financial officer
Feb 05, 2024
mattessich antony c.
acquired
95,460
4.86
19,642
president and ceo

1–10 of 50

Which funds bought or sold OCUL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Relyea Zuckerberg Hanson LLC
unchanged
-
-39,776
120,384
0.02%
Jul 16, 2024
DELTEC ASSET MANAGEMENT LLC
added
9.57
-3,795,750
17,717,400
3.39%
Jul 16, 2024
SJS Investment Consulting Inc.
unchanged
-
-373
1,129
-%
Jul 12, 2024
Rosalind Advisors, Inc.
new
-
5,130,000
5,130,000
3.95%
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-263,000
-
-%
Jul 10, 2024
CWM, LLC
new
-
-
-
-%
Jul 10, 2024
Founders Capital Management
unchanged
-
-4,520
13,680
0.01%
Jul 10, 2024
Simplicity Wealth,LLC
unchanged
-
-65,511
198,271
-%
Jul 09, 2024
DUDLEY & SHANLEY, INC.
new
-
110,808
110,808
0.02%
Jul 09, 2024
TRUST CO OF VERMONT
added
3.33
-12,192
42,408
-%

1–10 of 46

Are Funds Buying or Selling OCUL?

Are funds buying OCUL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OCUL
No. of Funds

Unveiling Ocular Therapeutix Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 27, 2024
summer road llc
9.4%
14,360,633
SC 13D/A
Feb 14, 2024
opaleye management inc.
5.51%
6,070,000
SC 13G/A
Feb 13, 2024
vanguard group inc
4.46%
5,118,102
SC 13G/A
Jan 31, 2024
blackrock inc.
5.2%
5,761,533
SC 13G/A
Dec 28, 2023
venrock healthcare capital partners iii, l.p.
6.8%
7,775,760
SC 13G
Dec 22, 2023
deep track capital, lp
8.38%
9,230,769
SC 13G
Dec 18, 2023
summer road llc
11.6%
13,429,782
SC 13D/A
Feb 13, 2023
opaleye management inc.
7.89%
6,075,000
SC 13G/A
Feb 09, 2023
vanguard group inc
5.16%
3,976,853
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
4,952,737
SC 13G/A

Recent SEC filings of Ocular Therapeutix Inc

View All Filings
Date Filed Form Type Document
Jul 17, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 15, 2024
144
Notice of Insider Sale Intent
Jul 12, 2024
144
Notice of Insider Sale Intent
Jul 09, 2024
144
Notice of Insider Sale Intent
Jun 17, 2024
S-8
Employee Benefits Plan
Jun 14, 2024
8-K
Current Report
Jun 04, 2024
3
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 03, 2024
8-K
Current Report

Peers (Alternatives to Ocular Therapeutix Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Ocular Therapeutix Inc News

Latest updates
StockTitan29 hours ago

Ocular Therapeutix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-0.2%14,77414,80215,08115,18613,37414,07611,96512,26613,18712,30912,15311,7187,3427,3495,8761,5692,6092,256829650492
Costs and Expenses33.1%46,39134,85134,29535,75635,92333,43733,50932,18231,02030,35831,68231,94927,57021,69219,88219,45319,22323,65723,97322,24920,150
  S&GA Expenses10.1%10,1839,2469,31511,15310,83510,53310,18610,1409,0639,1379,5768,3918,0866,8116,5206,1537,1307,1426,7777,2253,347
  R&D Expenses28.0%20,73516,19515,01915,09414,74713,54313,71913,10013,10012,57812,71913,85910,9277,6246,9518,0216,09810,12510,2359,41411,317
Interest Expenses-2.4%4,0514,1523,4261,9911,7681,8471,7971,6961,6831,6801,6581,6551,6791,7261,7151,6941,6331,8051,6511,6271,018
Net Income-121.9%-64,848-29,220-516-20,682-30,318-15,542-24,188-18,766-12,542-3,8502,657-8,4813,121-85,612-11,944-36,568-21,512-26,017-18,778-24,453-17,124
Net Income Margin-39.4%-1.93*-1.38*-1.16*-1.66*-1.72*-1.38*-1.19*-0.65*-0.45*-0.15*-2.29*-3.19*---------
Free Cashflow-49.0%-34,142-22,913-7,991-22,065-23,352-19,108-13,963-11,371-18,876-15,784-13,258-20,185---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets113.8%53925216212312914915917318820521823124326298.0010773.0079.0089.0090.00101
  Current Assets123.8%52023214110110713014616017519120421722824682.0090.0055.0060.0070.0065.0079.00
    Cash Equivalents146.6%48319611167.0079.0010412113514516417919220923071.0084.0048.0056.0065.0062.0076.00
  Inventory11.7%3.002.002.002.002.002.002.002.001.001.001.001.001.001.001.001.001.001.001.001.000.00
  Net PPE-2.5%11.0012.0012.0013.0012.0010.007.007.007.007.007.007.008.008.008.009.009.0010.0010.0011.0011.00
Liabilities-18.6%13116115511911911411210710811713015016018610210284.0082.0077.0081.0076.00
  Current Liabilities-30.4%24.0035.0035.0032.0030.0031.0029.0026.0024.0026.0025.0022.0027.0027.0023.0014.0011.0012.0011.0010.009.00
  Long Term Debt-100.0%-9.009.0030.0029.0029.0028.0028.0027.0026.0026.0025.0025.0024.0024.0026.0025.0024.0023.0024.0023.00
    LT Debt, Non Current-100.0%-9.009.0030.0029.0029.0028.0028.0027.0026.0026.0025.0025.0024.0024.0026.0025.0024.0023.0024.0023.00
Shareholder's Equity347.7%40891.008.003.0010.0035.0046.0066.0080.0088.0087.0080.0083.0076.00-5.00--11.008.0026.00
  Retained Earnings-9.3%-762-697-668-667-647-616-601-577-558-545-541-544-536-539-453-441-405-383-357-338-314
  Additional Paid-In Capital48.4%1,170789676671657652648643638634629625620615450447394380369347340
Shares Outstanding34.6%15511579.0079.0077.0077.0077.0077.0077.0076.0076.0076.00---------
Float----406---284---1,079---478---169-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-50.9%-33,887-22,454-7,732-20,075-19,973-16,958-13,169-10,876-18,600-15,153-12,982-20,056-17,359-6,246-13,658-14,796-18,854-19,467-19,544-19,181-19,386
  Share Based Compensation84.3%7,9784,3284,5124,4134,5724,2344,2404,2814,2093,8413,7584,2923,0862,1041,9361,8261,6651,9533,1691,6951,942
Cashflow From Investing44.4%-255-459-259-1,990-3,379-2,150-794-495-276-631-276-129-158-253-214-125-249-601-419-493-725
Cashflow From Financing197.0%321,223108,17051,9359,64578.004583744931296676792,667-1,162163,91322051,06312,8189,09118,6125,33842,300
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OCUL Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue, net$ 14,774$ 13,374
Costs and operating expenses:  
Cost, Product and Service [Extensible List]Product revenue, netProduct revenue, net
Cost of product revenue$ 1,326$ 1,214
Research and development20,73514,747
Selling and marketing10,18310,835
General and administrative14,1479,127
Total costs and operating expenses46,39135,923
Loss from operations(31,617)(22,549)
Other income (expense):  
Interest income3,922563
Interest expense(4,051)(1,768)
Change in fair value of derivative liabilities(5,152)(6,563)
Loss on extinguishment of debt(27,950) 
Other expense (1)
Total other income (expense), net(33,231)(7,769)
Net loss$ (64,848)$ (30,318)
Net loss per share, basic (in dollars per share)$ (0.49)$ (0.39)
Weighted average common shares outstanding, basic (in shares)132,021,94577,386,287
Net loss per share, diluted (in dollars per share)$ (0.49)$ (0.39)
Weighted average common shares outstanding, diluted (in shares)132,021,94577,386,287
Product revenue, net  
Revenue:  
Total revenue, net$ 14,715$ 13,214
Collaboration revenue  
Revenue:  
Total revenue, net$ 59$ 160

OCUL Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 482,888$ 195,807
Accounts receivable, net26,54626,179
Inventory2,5742,305
Restricted cash150150
Prepaid expenses and other current assets7,6667,794
Total current assets519,824232,235
Property and equipment, net11,45011,739
Restricted cash1,6141,614
Operating lease assets6,0596,472
Total assets538,947252,060
Current liabilities:  
Accounts payable6,4534,389
Accrued expenses and other current liabilities16,04028,666
Deferred revenue263255
Operating lease liabilities1,5421,586
Total current liabilities24,29834,896
Other liabilities:  
Operating lease liabilities, net of current portion6,4076,878
Derivative liabilities19,62429,987
Deferred revenue, net of current portion14,06814,135
Notes payable, net66,45665,787
Other non-current liabilities111108
Convertible Notes, net 9,138
Total liabilities130,964160,929
Commitments and contingencies (Note 14)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 154,704,086 and 114,963,193 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively1512
Additional paid-in capital1,170,394788,697
Accumulated deficit(762,426)(697,578)
Total stockholders' equity407,98391,131
Total liabilities and stockholders' equity$ 538,947$ 252,060
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEocutx.com
 INDUSTRYBiotechnology
 EMPLOYEES274

Ocular Therapeutix Inc Frequently Asked Questions


What is the ticker symbol for Ocular Therapeutix Inc? What does OCUL stand for in stocks?

OCUL is the stock ticker symbol of Ocular Therapeutix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocular Therapeutix Inc (OCUL)?

As of Fri Jul 19 2024, market cap of Ocular Therapeutix Inc is 1.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers. The fair value of Ocular Therapeutix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocular Therapeutix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCUL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocular Therapeutix Inc a good stock to buy?

The fair value guage provides a quick view whether OCUL is over valued or under valued. Whether Ocular Therapeutix Inc is cheap or expensive depends on the assumptions which impact Ocular Therapeutix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUL.

What is Ocular Therapeutix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, OCUL's PE ratio (Price to Earnings) is -10.55 and Price to Sales (PS) ratio is 20.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUL PE ratio will change depending on the future growth rate expectations of investors.